MB
Michaela Bazo
Co-founder, MetaNova (Bittensor Subnet 68)
Profile Overview
Michaela Bazo is featured as a builder using decentralized AI infrastructure to attack one of drug discovery's ugliest bottlenecks: search cost. In the episode, MetaNova is less a generic biotech startup and more a coordination system that uses Bittensor incentives to widen and accelerate molecular screening.
What the episodes support
- MetaNova uses Bittensor Subnet 68 to distribute molecular screening work across a decentralized network.
- The company's pitch is that decentralized search can reduce drug discovery cost and expand the number of candidate molecules explored.
- The founder narrative is about turning incentive design into scientific throughput.
Evidence in the corpus
- The episode summary says Bittensor Subnet 68 crowdsources screening of 65 billion molecules and aims to cut drug development costs by up to 50 percent.
- The topics explicitly include decentralized AI, Metanova Labs, molecular screening, and healthcare costs.
Source discipline
This profile is constrained to claims grounded in the episode and linked entity pages. No speculative biography, no invented operating history, and no unsourced praise.
Appearance history
E2267This Bittensor Subnet Could Cut Drug Discovery Costs in HALF